REFERENCES
2. Timmis A, Townsend N, Gale CP, et al. European society of cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41:12-85.
3. Perrino C. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Investig. 2006;116:1547-60.
4. Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43:2549-61.
5. Schirone L, Forte M, D’ambrosio L, et al. An overview of the molecular mechanisms associated with myocardial ischemic injury: state of the art and translational perspectives. Cells. 2022;11:1165.
6. Micheel J, Safrastyan A, Wollny D. Advances in non-coding RNA sequencing. Noncoding RNA. 2021;7:70.
7. Gao J, Xu W, Wang J, Wang K, Li P. The role and molecular mechanism of non-coding RNAs in pathological cardiac remodeling. Int J Mol Sci. 2017;18:608.
8. Jha S, Thasma Loganathbabu VK, Kumaran K, Krishnasamy G, Aruljothi KN. Long non-coding RNAs (lncRNAs) in heart failure: a comprehensive review. Noncoding RNA. 2023;10:3.
9. Shen S, Jiang H, Bei Y, Xiao J, Li X. Long non-coding RNAs in cardiac remodeling. Cell Physiol Biochem. 2017;41:1830-7.
10. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE. 2012;7:e30733.
11. Zhang C, Huo ST, Wu Z, et al. Rapid development of targeting circRNAs in cardiovascular diseases. Mol Ther Nucleic Acids. 2020;21:568-76.
12. Ding C, Zhou Y. Insights into circular RNAs: biogenesis, function and their regulatory roles in cardiovascular disease. J Cell Mol Med. 2023;27:1299-314.
13. Joaquim VHA, Pereira NP, Fernandes T, Oliveira EM. Circular RNAs as a diagnostic and therapeutic target in cardiovascular diseases. Int J Mol Sci. 2023;24:2125.
14. Wang X, Shan G. Features and biomedical relevance of circular RNA biogenesis. Trends Genet. 2026;42:282-94.
15. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384-8.
16. Zhou W, Cai Z, Liu J, Wang D, Ju H, Xu R. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19:172.
17. Hwang HJ, Kim YK. Molecular mechanisms of circular RNA translation. Exp Mol Med. 2024;56:1272-80.
18. Capirossi G, Brasini S, Tremoli E, Binatti A, Roncarati R. Circular RNAs in cardiovascular physiopathology: from molecular mechanisms to therapeutic opportunities. Int J Mol Sci. 2025;26:9725.
20. Geng H, Li R, Su Y, et al. The circular RNA Cdr1as promotes myocardial infarction by mediating the regulation of miR-7a on its target genes expression. PLoS ONE. 2016;11:e0151753.
21. Wang L, Yu P, Wang J, et al. Downregulation of circ-ZNF609 promotes heart repair by modulating RNA N6-methyladenosine-modified Yap expression. Research. 2022;2022:9825916.
22. Yu P, Wang J, Xu G, et al. RNA m6A-regulated circ-ZNF609 suppression ameliorates doxorubicin-induced cardiotoxicity by upregulating FTO. JACC Basic Transl Sci. 2023;8:677-98.
23. Zhu Y, Zhao P, Sun L, et al. Overexpression of circRNA SNRK targets miR-103-3p to reduce apoptosis and promote cardiac repair through GSK3β/β-catenin pathway in rats with myocardial infarction. Cell Death Discov. 2021;7:84.
24. Yuan Q, Sun Y, Yang F, et al. CircRNA DICAR as a novel endogenous regulator for diabetic cardiomyopathy and diabetic pyroptosis of cardiomyocytes. Sig Transduct Target Ther. 2023;8:99.
25. Wang D, Tian L, Wang Y, Gao X, Tang H, Ge J. Circ_0001206 regulates miR-665/CRKL axis to alleviate hypoxia/reoxygenation-induced cardiomyocyte injury in myocardial infarction. ESC Heart Fail. 2022;9:998-1007.
26. Li Y, Ren S, Xia J, Wei Y, Xi Y. EIF4A3-induced circ-BNIP3 aggravated hypoxia-induced injury of H9c2 cells by targeting miR-27a-3p/BNIP3. Mol Ther Nucleic Acids. 2020;19:533-45.
27. Li D, You J, Mao C, et al. Circular RNA Fbxl5 regulates cardiomyocyte apoptosis during ischemia reperfusion injury via sponging microRNA-146a. J Inflamm Res. 2022;15:2539-50.
28. Wang L, Feng J, Feng X, et al. Exercise-induced circular RNA circUtrn is required for cardiac physiological hypertrophy and prevents myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2023;119:2638-52.
29. Gao X, Liu C, Zhang Y, et al. The circRNA CNEACR regulates necroptosis of cardiomyocytes through Foxa2 suppression. Cell Death Differ. 2021;29:527-39.
30. Ju J, Li X, Zhao X, et al. Circular RNA FEACR inhibits ferroptosis and alleviates myocardial ischemia/reperfusion injury by interacting with NAMPT. J Biomed Sci. 2023;30:45.
31. Lu D, Chatterjee S, Xiao K, et al. A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. Eur Heart J. 2022;43:4496-511.
32. Shen M, Wu Y, Li L, Zhang L, Liu G, Wang R. CircMAP3K5 promotes cardiomyocyte apoptosis in diabetic cardiomyopathy by regulating miR‐22‐3p/DAPK2 Axis. J Diabetes. 2023;16:e13471.
33. Pitoulis FG, Terracciano CM. Heart plasticity in response to pressure- and volume-overload: a review of findings in compensated and decompensated phenotypes. Front Physiol. 2020;11:92.
34. Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245-62.
35. Li M, Ding W, Fang X, et al. Novel truncated peptide derived from circCDYL exacerbates cardiac hypertrophy. Circ Res. 2025;136:e94-112.
36. Pan W, Hunkler HJ, Chatterjee S, et al. A circular RNA derived from the ryanodine receptor 2 locus controls cardiac hypertrophy and calcium handling. Cell Mol Life Sci. 2025;82:359.
37. Yang M, Wang W, Wang L, Li Y. Circ_0001052 promotes cardiac hypertrophy via elevating Hipk3. Aging. 2023;15:204521.
38. Wang K, Long B, Liu F, et al. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur Heart J. 2016;37:2602-11.
39. Xu Q, Liu J, Zhu R, et al. NSD2 promotes pressure overload-induced cardiac hypertrophy via activating circCmiss1/TfR1/ferroptosis signaling. Life Sci. 2023;328:121873.
40. Pan J, Xu Z, Guo G, et al. Circ_nuclear factor I X (circNfix) attenuates pressure overload-induced cardiac hypertrophy via regulating miR-145-5p/ATF3 axis. Bioengineered. 2021;12:5373-85.
41. Li H, Xu J, Fang X, et al. Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4. Cardiovasc Res. 2020;116:1323-34.
42. Lin X, Zhang L, Zhang W, Lei X, Lu Q, Ma A. Circular RNA circ_0001006 aggravates cardiac hypertrophy via miR-214-3p/PAK6 axis. Aging. 2022;14:2210-20.
43. Miličić D, Jakuš N, Fabijanović D. Microcirculation and heart failure. Curr Pharm Des. 2018;24:2954-9.
44. Vancheri F, Longo G, Vancheri S, Henein M. Coronary microvascular dysfunction. J Clin Med. 2020;9:2880.
45. Si X, Zheng H, Wei G, et al. circRNA Hipk3 induces cardiac regeneration after myocardial infarction in mice by binding to notch1 and miR-133a. Mol Ther Nucleic Acids. 2020;21:636-55.
46. Li B, Bai W, Guo T, et al. Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1. Nat Commun. 2024;15:2953.
47. Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125-34.
48. Liao J, Wu J, Wang Y, et al. Deep sequencing reveals a global reprogramming of lncRNA transcriptome during EMT. Biochim Biophys Acta Mol Cell Res. 2017;1864:1703-13.
49. Madè A, Bibi A, Garcia-Manteiga JM, et al. circRNA-miRNA-mRNA deregulated network in ischemic heart failure patients. Cells. 2023;12:2578.
50. Yamada Y, Sadahiro T, Nakano K, et al. Cardiac reprogramming and Gata4 overexpression reduce fibrosis and improve diastolic dysfunction in heart failure with preserved ejection fraction. Circulation. 2025;151:379-95.
51. Wu N, Xu J, Du WW, et al. YAP circular RNA, circYap, attenuates cardiac fibrosis via binding with tropomyosin-4 and gamma-actin decreasing actin polymerization. Mol Ther. 2021;29:1138-50.
52. Du WW, Rafiq M, Yuan H, et al. A novel protein NAB1‐356 encoded by circRNA circNAB1 mitigates atrial fibrillation by reducing inflammation and fibrosis. Adv Sci. 2025;12:2411959.
53. Zhang L, Lou Q, Zhang W, et al. CircCAMTA1 facilitates atrial fibrosis by regulating the miR-214-3p/TGFBR1 axis in atrial fibrillation. J Mol Histol. 2022;54:55-65.
54. Du WW, Xu J, Yang W, et al. A neuroligin isoform translated by circNlgn contributes to cardiac remodeling. Circ Res. 2021;129:568-82.
55. Mei S, Ma X, Zhou L, et al. CircSMAD3 represses SMAD3 phosphorylation and ameliorates cardiac remodeling by recruiting YBX1. iScience. 2024;27:111305.
56. Jung M, Schmidt A, Sansonetti M, et al. Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction. Eur Heart J. 2026;47:2831-47.
57. Jeong A, Lim Y, Kook T, et al. Circular RNA circSMAD4 regulates cardiac fibrosis by targeting miR-671-5p and FGFR2 in cardiac fibroblasts. Mol Ther Nucleic Acids. 2023;34:102071.
58. Wang Y, Wang H, Zhang L, Zhang J, Liu N, Zhao P. A novel identified circular RNA, circSnap47, promotes heart failure progression via regulation of miR-223-3p/MAPK axis. Mol Cell Biochem. 2022;478:459-69.
59. Schmidt A, Schmidt K, Groß S, et al. Circular RNA circIGF1R controls cardiac fibroblast proliferation through regulation of carbohydrate metabolism. Sci Rep. 2025;15:20331.
60. Bibi A, Madè A, Greco S, et al. Circular PVT1 promotes cardiac fibroblast activation interacting with miR-30a-5p and miR-125b-5p. Cell Death Dis. 2025;16:325.
61. Yan J, Ai C, Chen Q, et al. CircMap4k2 reactivated by aneurysm plication alleviates residual cardiac remodeling after SVR by enhancing cardiomyocyte proliferation in post-MI mice. J Adv Res. 2024;65:227-38.
62. Ma GB, Chen WX, Zhan FJ, et al. Circ_0002295 facilitated myocardial fibrosis progression through the miR‐1287/CXCR2 axis. Clin Exp Pharmacol Physiol. 2023;50:944-53.
63. Wang Y, Li C, Zhao R, et al. CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction. Theranostics. 2021;11:6315-33.
64. Jiang Y, Zhang B, Zhang B, et al. A novel feedback loop: CELF1/circ-CELF1/BRPF3/KAT7 in cardiac fibrosis. Acta Pharm Sin B. 2025;15:5192-211.
65. Guo J, Chen L, Huang Z, et al. Suppression of the inhibitory effect of circ_0036176-translated Myo9a-208 on cardiac fibroblast proliferation by miR-218-5p. J Cardiovasc Transl Res. 2022;15:548-59.
66. Pang P, Si W, Wu H, et al. The circular RNA circHelz enhances cardiac fibrosis by facilitating the nuclear translocation of YAP1. Transl Res. 2023;257:30-42.
67. Sun LY, Zhao JC, Ge XM, Zhang H, Wang CM, Bie ZD. Circ_LAS1L regulates cardiac fibroblast activation, growth, and migration through miR‐125b/SFRP5 pathway. Cell Biochem Funct. 2020;38:443-50.
68. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128:1487-513.
69. Sun Q, Karwi QG, Wong N, Lopaschuk GD. Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond. Cardiovasc Res. 2024;120:1996-2016.
70. Gibb AA, Hill BG. Metabolic coordination of physiological and pathological cardiac remodeling. Circ Res. 2018;123:107-28.
71. Zheng H, Huang S, Wei G, et al. CircRNA Samd4 induces cardiac repair after myocardial infarction by blocking mitochondria-derived ROS output. Mol Ther. 2022;30:3477-98.
72. Li F, Du WW, Li X, et al. A new protein isoform encoded by human circular RNA circSLC8a1 contributes to cardiac remodelling. Cardiovasc Res. 2025;121:882-99.
73. Chen X, Xu H, Zhao X, et al. PYRCR alleviates myocardial ischemia/reperfusion injury in mice via inhibiting DRG2-mediated cardiomyocyte pyroptosis. Acta Pharmacol Sin. 2025;46:3204-16.
74. Ni X, Duan L, Bao Y, et al. Circ_005077 accelerates myocardial lipotoxicity induced by high-fat diet via CyPA/p47PHOX mediated ferroptosis. Cardiovasc Diabetol. 2024;23:129.
75. Wang Z, Liu X, Deng Y. Negative feedback of SNRK to circ-SNRK regulates cardiac function post-myocardial infarction. Cell Death Differ. 2021;29:709-21.
76. Juni RP, Phelp PG, Bink DI, et al. COVID19 impairs cardiac function via endothelial H19 and IL6 signaling. Circ Res. 2023;132:648-51.
77. Robinson EL, Baker AH, Brittan M, et al. Dissecting the transcriptome in cardiovascular disease. Cardiovasc Res. 2022;118:1004-19.
78. Zhou Q, Boeckel JN, Yao J, et al. Diagnosis of acute myocardial infarction using a combination of circulating circular RNA cZNF292 and clinical information based on machine learning. MedComm. 2023;4:e299.
79. Sun Y, Jiang X, Lv Y, et al. Circular RNA expression profiles in plasma from patients with heart failure related to platelet activity. Biomolecules. 2020;10:187.
80. Chen C, Shen H, Huang Q, Li Q. The circular RNA CDR1as regulates the proliferation and apoptosis of human cardiomyocytes through the miR-135a/HMOX1 and miR-135b/HMOX1 axes. Genet Test Mol Biomarkers. 2020;24:537-48.
81. He S, Zhu H, Zhang J, Yang X, Zhao L. Genome-wide screening for circRNAs in epicardial adipose tissue of heart failure patients with preserved ejection fraction. Am J Transl Res. 2023;15:4610-9.
82. Costa MC, Calderon-Dominguez M, Mangas A, et al. Circulating circRNA as biomarkers for dilated cardiomyopathy etiology. J Mol Med. 2021;99:1711-25.
83. Han J, Zhang L, Hu L, et al. Circular RNA-expression profiling reveals a potential role of Hsa_circ_0097435 in heart failure via sponging multiple MicroRNAs. Front Genet. 2020;11:212.
84. Yan H, Du D, Wang C, Tian M. Downregulation of autophagy-related circular RNA (ACR) is correlated with poor survival of patients with chronic heart failure. Bioengineered. 2022;13:13141-9.
85. Feng Y, Yan B, Cheng H, et al. Knockdown circ_0040414 inhibits inflammation, apoptosis and promotes the proliferation of cardiomyocytes via miR‐186‐5p/PTEN/AKT axis in chronic heart failure. Cell Biol Int. 2021;45:2304-15.
86. Xu S, Zhang G, Tan X, et al. Differential expression spectrum of circRNA in plasma exosomes in dilated cardiomyopathy with heart failure. J Cell Mol Med. 2024;28:e70258.
87. Collado A, Gan L, Tengbom J, Kontidou E, Pernow J, Zhou Z. Extracellular vesicles and their non‐coding RNA cargos: emerging players in cardiovascular disease. J Physiol. 2022;601:4989-5009.
88. Ge X, Meng Q, Zhuang R, et al. Circular RNA expression alterations in extracellular vesicles isolated from murine heart post ischemia/reperfusion injury. Int J Cardiol. 2019;296:136-40.
89. Liu X, Zheng M, Han R, et al. Circulating exosomal CircRNAs as diagnostic biomarkers for chronic coronary syndrome. Metabolites. 2023;13:1066.
90. Liu X, Zhang Y, Yuan W, et al. Exosomal CircRNAs in circulation serve as diagnostic biomarkers for acute myocardial infarction. Front Biosci. 2024;29:149.
91. Yang D, Zhang W, Zhang H, et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics. 2020;10:3684-707.
92. Li S, Li X, Xue W, et al. Screening for functional circular RNAs using the CRISPR-Cas13 system. Nat Methods. 2020;18:51-9.
93. Holdt LM, Kohlmaier A, Teupser D. Circular RNAs as therapeutic agents and targets. Front Physiol. 2018;9:1262.
94. Lavenniah A, Luu TDA, Li YP, et al. Engineered circular RNA sponges act as miRNA inhibitors to attenuate pressure overload-induced cardiac hypertrophy. Mol Ther. 2020;28:1506-17.
95. Wu H, Zhou C, Gao Y, et al. circSP199a, a circularized RNA sponge targeting miR-199a-5p and -3p, mitigates mouse cardiac hypertrophy and fibrosis. Acta Pharmacol Sin. 2025;47:86-102.
96. Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629.
97. Inglut CT, Sorrin AJ, Kuruppu T, et al. Immunological and toxicological considerations for the design of liposomes. Nanomaterials. 2020;10:190.
98. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982-7015.
99. Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Sig Transduct Target Ther. 2023;8:341.
100. Qiu M, Li Y, Bloomer H, Xu Q. Developing biodegradable lipid nanoparticles for intracellular mRNA delivery and genome editing. Acc Chem Res. 2021;54:4001-11.
